{"id":64965,"date":"2026-05-11T12:28:39","date_gmt":"2026-05-11T04:28:39","guid":{"rendered":"https:\/\/flcube.com\/?p=64965"},"modified":"2026-05-11T12:28:40","modified_gmt":"2026-05-11T04:28:40","slug":"henlius-biotech-receives-fda-clearance-for-phase-i-trial-of-hlx05-n-cetuximab-biosimilar-in-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64965","title":{"rendered":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced it has received <strong>Investigational New Drug (IND) clearance<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> to initiate a <strong>Phase I clinical study<\/strong> evaluating its <strong>HLX05-N biosimilar<\/strong>\u2014a copy of <strong>Merck KGaA&#8217;s Erbitux (cetuximab)<\/strong>\u2014in patients with <strong>metastatic colorectal cancer (mCRC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-timeline\">Regulatory &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Jurisdiction<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Chinese Clinical Trial Approval<\/strong><\/td><td>NMPA (China)<\/td><td>Granted April 2026<\/td><\/tr><tr><td><strong>U.S. IND Clearance<\/strong><\/td><td>FDA (United States)<\/td><td>Granted May 2026<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Erbitux (cetuximab)<\/td><td>Merck KGaA\/Daiichi Sankyo<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Metastatic Colorectal Cancer (mCRC)<\/td><td>First-line and refractory settings<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>This dual-jurisdiction approval strategy positions Henlius to pursue simultaneous development pathways in both the world&#8217;s largest pharmaceutical markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-mechanism-amp-therapeutic-profile\">Drug Mechanism &amp; Therapeutic Profile<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-molecular-target-amp-action\">Molecular Target &amp; Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Epidermal Growth Factor Receptor (EGFR) expressed on normal and tumor cells<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Competitive inhibition of ligand binding (EGF, TGF-\u03b1) to EGFR<\/li>\n\n\n\n<li><strong>Downstream Effects<\/strong>:<\/li>\n\n\n\n<li>Blocks receptor phosphorylation and kinase activation<\/li>\n\n\n\n<li>Inhibits tumor cell proliferation and growth<\/li>\n\n\n\n<li>Induces programmed cell death (apoptosis)<\/li>\n\n\n\n<li>Reduces matrix metalloproteinase production<\/li>\n\n\n\n<li>Decreases vascular endothelial growth factor (VEGF) expression<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-significance-in-mcrc\">Clinical Significance in mCRC<\/h3>\n\n\n\n<p>Cetuximab represents a cornerstone therapy in EGFR-positive metastatic colorectal cancer, particularly in RAS wild-type patients. The biosimilar HLX05-N aims to provide cost-effective access to this established biologic while maintaining comparable efficacy and safety profiles.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-implications\">Strategic Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biosimilar Opportunity<\/strong>: U.S. cetuximab market valued at approximately $1.2 billion annually, with patent expiration creating significant biosimilar entry opportunities<\/li>\n\n\n\n<li><strong>Global Development Strategy<\/strong>: FDA clearance validates Henlius&#8217; international regulatory capabilities and quality standards<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Positions Henlius among leading Chinese biosimilar developers targeting Western markets, alongside companies like Innovent and Bio-Thera Solutions<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Successful U.S. approval could contribute $200-400 million in annual revenue by 2030, representing 15-25% of current company revenue<\/li>\n<\/ul>\n\n\n\n<p>The Phase I trial will primarily assess safety, pharmacokinetics, and immunogenicity compared to the reference Erbitux product, with subsequent phases planned to demonstrate clinical equivalence in larger patient populations.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial potential for HLX05-N. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics in the oncology biosimilar market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051000016_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051000016_c.\"><\/object><a id=\"wp-block-file--media-dd2128c0-4bf1-47bd-b964-eaa66caba800\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051000016_c.pdf\">2026051000016_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051000016_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dd2128c0-4bf1-47bd-b964-eaa66caba800\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,62,270,862,120],"class_list":["post-64965","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biosimilars","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA&#039;s Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64965\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA&#039;s Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64965\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T04:28:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-11T04:28:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer\",\"datePublished\":\"2026-05-11T04:28:39+00:00\",\"dateModified\":\"2026-05-11T04:28:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\",\"Merck\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64965#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64965\",\"name\":\"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-11T04:28:39+00:00\",\"dateModified\":\"2026-05-11T04:28:40+00:00\",\"description\":\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA's Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64965\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64965#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA's Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64965","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer","og_description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA's Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).","og_url":"https:\/\/flcube.com\/?p=64965","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-11T04:28:39+00:00","article_modified_time":"2026-05-11T04:28:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64965#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64965"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer","datePublished":"2026-05-11T04:28:39+00:00","dateModified":"2026-05-11T04:28:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64965"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696","Merck"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64965#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64965","url":"https:\/\/flcube.com\/?p=64965","name":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-11T04:28:39+00:00","dateModified":"2026-05-11T04:28:40+00:00","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar\u2014a copy of Merck KGaA's Erbitux (cetuximab)\u2014in patients with metastatic colorectal cancer (mCRC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64965#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64965"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64965#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64965"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64965\/revisions"}],"predecessor-version":[{"id":64967,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64965\/revisions\/64967"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}